血浆置换序贯双重血浆分子吸附治疗慢加急性乙型肝炎肝衰竭患者疗效及短期生存分析*

doi:10.3969/j.issn.1672-5069.2019.01.023

摘要/Abstract

摘要： 目的本研究主要是观察血浆置换（PE）序贯双重血浆分子吸附(DPMAS)治疗乙型肝炎相关性慢加急性肝衰竭（ACLF）患者的疗效。方法在83例ACLF患者,采用PE序贯DPMAS治疗,随访90 d。结果在本组83例ACLF患者中,早期29例,中期34例和晚期20例;在治疗90 d,早期生存率为65.5%,中期为38.2%,而晚期为15.0%（P<0.001）;早中晚期ACLF患者肝性脑病发生率分别为20.7%、52.9%和60.0%（P<0.05）;多因素COX回归分析显示,肝衰竭晚期（P=0.01）,肝性脑病≥II级（P=0.001）,血清TBIL≥350 μmol/L（P=0.008）和CLIF-SOFA≥10分（P=0.043）是ACLF患者死亡的独立危险因素。结论 PE序贯DPMAS可有效降低血清胆红素水平,而对肾功能无不利影响,从而可以明显改善患者整体生存率,且对早中期患者疗效较好,仍需扩大研究进一步证实。肝衰竭晚期,肝性脑病≥II期,血清TBIL≥350 μmol/L或CLIF-SOFA≥10分患者预后不良。

关键词: 慢加急性肝衰竭, 血浆置换, 双重血浆分子吸附, 治疗

Abstract: Objective The prognosis of patients with ACLF is extremely poor with mortality rates ranging from 30% to 70%. Hemoperfusion,plasma exchange（PE） and double plasma molecular absorb system （DPMAS） are the most popular non-biological artificial liver support system applied in China. The present study was to evaluate the effects of PE and sequential DPMAS therapy on short survival in patients with hepatitis B virus-induced acute-on-chronic liver failure （HBV-ACLF）. Method 83 patients at different stages of HBV-ACLF were recruited in Xijing hospital between January 2011 and December 2016. All the laboratory parameters were collected at admission,before and after artificial liver support system therapy,and at the end of 90 day follow up. Result There were 29 cases at early stage,34 cases at middle stage and 20 cases at advanced stage at admission in this series of 83 patients with HBV-ACLF. At the end of 90 days of treatment,the survival rate in patients at early stage was 65.5%,in patients at middle stage was 38.2%,and in patients at advanced stage was 15.0% （P<0.001）;The incidence rates of hepatic encephalopathy in patients at early,middle and advanced stage were 20.7%,52.9% and 60.0% （P<0.05）;Multivariate Logistic regression analysis showed that the advanced stage（P=0.01）,serum bilirubin level being ≥350 μmol/L（P=0.008）,hepatic encephalopathy being≥grade 2（P=0.001） and CLIF-SOFA being≥10（P=0.043） at presentation were the independent risk factors of mortality in patients with HBV ACLF. Conclusion Sequential PE and DPMAS therapy might remove toxin from blood,improve the overall survival rate,and the efficacy is obvious in patients at early and middle stage,which still needs further investigation. Patients at admission have serum bilirubin levels ≥350 μmol/L,with hepatic encephalopathy≥grade 2,CLIF-SOFA scores≥10 and at advanced stage might hint poor prognosis.

Key words: Acute-on-chronic liver failure, Artificial liver support system, Plasma exchange, Double plasma molecular absorb system, Therapy

张静, 尹芳, 罗贯虹, 王海英, 郑洋洋, 李娜, 周新民. 血浆置换序贯双重血浆分子吸附治疗慢加急性乙型肝炎肝衰竭患者疗效及短期生存分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 85-88.

Zhang Jing, Yin Fang, Luo Guanhong, et al.. Effect of plasma exchange and sequential double plasma molecular adsorbent therapy on short survival in patients with hepatitis B virus-induced acute on chronic liver failure[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 85-88.

参考文献

[1] Arroyo V,Moreau R,Jalan R,et al.Study E-CCC: Acute-on-chronic liver failure:A new syndrome that will re-classify cirrhosis. J Hepatol,2015,62(Suppl 1):S131-143.
[2] You S,Rong Y,Zhu B,et al.Changing etiology of liver failure in 3 916 patients from northern China:a 10-year survey. Hepatol Int,2013,7(2):714-720.
[3] Basto ST,Villela-Nogueira CA,Tura BR,et al.Risk factors for long-term mortality in a large cohort of patients wait-listed for liver transplantation in Brazil. Liver Transpl 2011,17:1013-1020.
[4] Chen JJ,Huang JR,Yang Q,et al.Plasma exchange-centered artificial liver support system in hepatitis b virus-related acute-on-chronic liver failure:A nationwide prospective multicenter study in China. Hepatobiliary Pancreat Dis Int,2016,15(3):275-281.
[5] Ding J,Han LP,Lou XP,et al.Effectiveness of combining plasma exchange with plasma perfusion in acute fatty liver of pregnancy:A retrospective analysis. Gynecol Obstet Invest,2015,79(2):97-100.
[6] 范晶华,陈红英,王宏图,等. 血浆置换联合血浆灌流治疗肝衰竭患者临床疗效分析. 实用肝脏病杂志,2016,19(3):184-187.
[7] 殷桂春,轧春妹,李谦,等. 两台血液灌流机组合实现双重血浆分子吸附系统治疗肝衰竭的临床研究. 中华危重病急救医学,2013,25(12):738-742.
[8] Wan YM,Li YH,Xu ZY,et al.Therapeutic plasma exchange versus double plasma molecular absorption system in hepatitis b virus-infected acute-on-chronic liver failure treated by entercavir: A prospective study. J Clin Apher,2017,3:1-7.
[9] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2012年版). 实用肝脏病杂志,2013,16(3):210-216.
[10] Moreau R,Jalan R,Gines P,et al.Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology,2013,144(7):1426-1437.
[11] 李晓东,徐东平. HBV相关慢加急性肝衰竭免疫病理发病机制研究进展. 实用肝脏病杂志,2015,5(18):7-10.
[12] Karvellas CJ,Subramanian RM.Current evidence for extracorporeal liver support systems in acute liver failure and acute-on-chronic liver failure. Crit Care Clin,2016,32(3):439-451.
[13] Li MQ,Ti JX,Zhu YH,et al.Combined use of non-biological artificial liver treatments for patients with acute liver failure complicated by multiple organ dysfunction syndrome. World J Emerg Med,2014,5(3):214-217.
[14] Yuan H,Chen S,Hu F,et al.Efficacy of two combinations of blood purification techniques for the treatment of multiple organ failure induced by wasp stings. Blood Purif,2016,42(1):49-55. [15] 刘菲菲,吴吉圆,张海月,等. 慢加急性乙型肝炎肝衰竭临床特征及血浆置换治疗对其预后的影响. 实用肝脏病学杂志,2016,19(2):188-191.
[16] Inoue K,Kourin A,Watanabe T,et al.Artificial liver support system using large buffer volumes removes significant glutamine and is an ideal bridge to liver transplantation. Transplant Proc,2009,41(1):259-261.
[17] Huang Z,Wang SR,Su W,et al.Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column. Ther Apher Dial,2010,14(6):596-602.
[18] Chen J,Han W,Su R,et al.Non-ionic macroporous polystyrene adsorbents for removal of serum toxins in liver failure by hemoperfusion. Artif Cells Nanomed Biotechnol,2017,45(1):174-183.
[19] Kribben A,Gerken G,Haag S,et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology,2012,142(4):782-789,ex783.
[20] Shen Y,Wang XL,Wang B,et al.Survival benefits with artificial liver support system for acute-on-chronic liver failure:A time series-based meta-analysis. Medicine (Baltimore),2016,95(3):e2506.
[21] Blasco-Algora S,Masegosa-Ataz J,Gutiérrez-García ML,et al.Acute-on-chronic liver failure:Pathogenesis,prognostic factors and management. World J Gastroenterol,2015,21(42):12125-12140.
[22] Hernaez R,Solà E,Moreau R,et al.Acute-on-chronic liver failure:an update. Gut,2017,66(3):541-553.
[23] Philips CA,Sarin SK.Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation. World J Gastroenterol,2014,20(43):16037-16052.
[24] Asrani SK,Simonetto DA,Kamath PS.Acute-on-chronic liver failure.Clin Gastroenterol Hepatol,2015,13(12):2128-2139.
[25] Kim TY,Song DS,Kim HY,et al.Characteristics and Discrepancies in acute-on-chronic liver failure:Need for a unified definition. PLoS One,2016,11(1):e0146745.

血浆置换序贯双重血浆分子吸附治疗慢加急性乙型肝炎肝衰竭患者疗效及短期生存分析^*

Effect of plasma exchange and sequential double plasma molecular adsorbent therapy on short survival in patients with hepatitis B virus-induced acute on chronic liver failure

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[5]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[6]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[7]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[8]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[9]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.
[10]	黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919.
[11]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[12]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.
[13]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[14]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[15]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.